EPO and anemia (phenotype): Chen et al. [31], conducting a phase III study (NCT02652806; n = 304) in patients with CKD treated with repeated hemodialysis or peritoneal dialysis, and for the last 6 weeks ESA, showed that roxadustat was as effective as erythropoietin alfa in the treatment of anemia.